A transwell migration assay showed that treatment of Panc02 PDAC cells with rNTN1 increased cancer cell migration, an effect that was reversed by CRISPR-mediated knockdown of Neo1 or co-treatment with the NEO1-blocking antibody (Supplementary Fig. S3A–C). Here, NEO1 is linked to cancer.